KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Goodwill (2020 - 2025)

Historic Goodwill for Supernus Pharmaceuticals (SUPN) over the last 6 years, with Q3 2025 value amounting to $119.1 million.

  • Supernus Pharmaceuticals' Goodwill rose 176.13% to $119.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.1 million, marking a year-over-year increase of 176.13%. This contributed to the annual value of $117.0 million for FY2024, which is 0.0% changed from last year.
  • Supernus Pharmaceuticals' Goodwill amounted to $119.1 million in Q3 2025, which was up 176.13% from $117.0 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Goodwill ranged from a high of $119.1 million in Q3 2025 and a low of $77.9 million during Q1 2021
  • For the 5-year period, Supernus Pharmaceuticals' Goodwill averaged around $110.8 million, with its median value being $117.0 million (2022).
  • Over the last 5 years, Supernus Pharmaceuticals' Goodwill had its largest YoY gain of 5083.36% in 2021, and its largest YoY loss of 1254.16% in 2021.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Goodwill stood at $117.5 million in 2021, then decreased by 0.42% to $117.0 million in 2022, then changed by 0.0% to $117.0 million in 2023, then changed by 0.0% to $117.0 million in 2024, then increased by 1.76% to $119.1 million in 2025.
  • Its Goodwill stands at $119.1 million for Q3 2025, versus $117.0 million for Q2 2025 and $117.0 million for Q1 2025.